New research indicates that overexpression of the transcription factor SOX9 restores the sensitivity of mouse and human melanomas to the anticancer agent retinoic acid, thereby stopping tumor growth. The authors suggest that a combined therapeutic strategy, increasing the expression of SOX9 while simultaneously treating with RA, may provide new hope to effectively treat RA-resistant cancers such as melanoma.